Trial closure: PA7
Published:Category: Trials
PA7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma trial has permanently closed.
Primary Publication
CRA Lunch and Learn training program
Published:Category: Group updates
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
CCTG is looking for a new gastro-intestinal patient representative
Published:Category: Group updates
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.
Read MoreThe CCTG Annual Spring Meeting of Participants is fast approaching!
Published:Category: Group updates
The CCTG Annual Spring Meeting of Participants is fast approaching! We are excited to share important updates and additional information.
Read MorePublication: PR17 and MA5
Published:Category: Publications
PR17 trial publication: Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Patients who inherited the adrenal-permissive HSD3B1 allele had more favorable 5-year clinical progression-free survival and OS when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen compared with their counterparts who did not have adrenal-permissive HSD3B1 inheritance.
Read MoreThe VU2 vulvar cancer evaluation trial has opened nationally
Published:Category: Trials
This pivotal study is a move away from current ‘one size fits all’ treatment approaches through the testing of a vulvar cancer patients’ tissue to determine the best treatment options. Researchers want to evaluate if the molecular features in tissues removed in the first surgery can direct the need for additional surgery versus a close follow-up for patients with vulvar squamous cell cancer.
Read MoreTrial closure: BLC4
Published:Category: Trials
The BLC4 (SWOG S1605): A Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer trial has permanently closed.
This phase II trial studied how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG).
Read MoreIn memory of patient representative Suzanne Wood
Published:Category: Group updates
CCTG is heartbroken to share the news that, following a long and courageous battle, Suzanne Wood the GI patient representative has passed away. She died at hospital in Toronto with family by her side at the age of 48 on February 9, 2025.
Read More